Huvepharma Announces Its Intention to Launch an Offering in 2021

Huvepharma Announces Its Intention to Launch an Offering and List on Euronext Amsterdam:

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR

IN THE UNITED STATES, CANADA, AUSTRALI OR JAPAN, OR ANY OTHER JURISDICTION IN

VIOLATION OF RELEVANT LAWS IN THIS JURISDICTION.

This announcement is an announcement in accordance with EU Prospectus Regulation 2017/1129 and the underlying legislation regarding the Company’s intention (as defined below) to proceed with the offer (as defined below) and admission (as below) defined) as described below). defined below). This announcement does not constitute a prospectus.

This announcement is for informational purposes only and is not intended to be and should not be construed as an offer to sell or solicitation of an offer of shares (as defined below) in any jurisdiction, including United States, Canada, Australia No. and when the Offer is made, further details regarding the Offer and the Admission will be included in the Prospectus (as defined below).

After the Prospectus has been approved by the Netherlands Authority for the Financial Markets (the “AFM”), the Prospectus will be published at the start of the offering period and made available free of charge on the company’s website. the company (www.huvepharma.com), subject to restrictions under the security laws of some jurisdictions.

An offer to purchase shares will be made in accordance with the Offer and any potential investor is expected to make its investment solely on the basis of the information to be included in the Prospectus. Potential investors should read the Prospectus before making any investment decision to fully understand the potential risks and rewards of investing in the Shares. The approval of the Prospectus by the AFM should not be construed as an approval of the quality of the Shares and the Company (as defined below).

HUVEPHARMA announces its intention to make an offer
EURONEXT AMSTERDAM LYS

Amsterdam, The Netherlands, June 14, 2021 – Huvepharma BV (the “Company”) and its subsidiaries (the “Group”), a global leader in animal health with a strong position in veterinary and feed additives, today announce plans to make an offer (the “Offer”) and is admitted to listing and trading its ordinary shares (the “Shares”) on Euronext Amsterdam (“Euronext Amsterdam”), a regulated market operated by Euronext Amsterdam NV (admission).

The offer must include a primary offering of shares just issued by the company and a secondary offering of shares held by the sole shareholder of the company, Advance Properties OOD (the “selling shareholder”). The offer is expected in the coming weeks, subject to market conditions and other relevant considerations.

HIGHLIGHTS OF HUVEPHARMA

The company is the fastest-growing global animal health company (in terms of revenue growth) and focuses on the development, production, and marketing of food and health products for animals and humans1. The global animal health market sold approximately $33 billion annually in 2019, of which approximately $20 billion, or 60% of the market, represents farm animals.

The company is the seventh-largest in sales of animal health (including vaccines for farm animals) and the second-largest in sales of swine and poultry health (excluding vaccines). With more than half a century of experience, the company is committed to providing quality products and services to help customers improve farm animal health.

With headquarters in the European Union and offices in Italy, France, Bulgaria, and the United States with a total of 13 offices, the company is highly self-sufficient; more than 95% of the end products are manufactured in-house.

According to Ventose, the farm animal segment in which the company operates (poultry, swine, cattle, sheep, and water) should grow at a CAGR of 5% (in nominal terms) by 2019 to 2024 – a faster pace in other areas of animal health, such as companion animals, which should have a CAGR of 2.5% over the same period (according to Vetnose).

Growth is mainly driven by three factors: increasing world population; a larger and growing middle class in developing countries that need more high-quality animal proteins; and concerns about food safety and the demand for higher quality standards have increased, leading to an increase in the demand for food.

Translate »